Delving into the Latest Updates on SHR-4394 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

SHR-4394

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Adenocarcinoma of prostate

Inactive Indication-

Originator Organization

Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Active Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The study aims to assess the safety and tolerability of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer, and determine the recommended Phase II dose (RP2D); To evaluate of the efficacy of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer based on Prostate-Specific Antigen (PSA) response rate.

Start Date01 Mar 2026

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

NCT06783829

/ RecruitingPhase 1

A Phase I Study of Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4394 Injection in Subjects With Prostate Cancer

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.

Start Date22 Jan 2025

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

ChiCTR2500096042

/ Not yet recruitingPhase 1IIT

Phase I clinical study of safety, tolerability, pharmacokinetics and efficacy of SHR-4394 for injection in patients with prostate cancer

Start Date01 Jan 2025

Sponsor / Collaborator